Neisseria gonorrhoeae ciprofloxacin susceptibility testing and gyrA targets - Authors' reply
- PMID: 37236213
- PMCID: PMC10994243
- DOI: 10.1016/S2666-5247(23)00150-7
Neisseria gonorrhoeae ciprofloxacin susceptibility testing and gyrA targets - Authors' reply
Conflict of interest statement
YHG receives or has received support from Wellcome Trust, Pfizer, and Merck; receives or has received consulting fees from GlaxoSmithKline, Quidel, and the National Basketball Association; receives or has received payment for expert testimony from Merck; and serves on the advisory board for Day Zero Diagnostics. DHFR and TDM declare no competing interests.
Comment on
-
Neisseria gonorrhoeae diagnostic escape from a gyrA-based test for ciprofloxacin susceptibility and the effect on zoliflodacin resistance: a bacterial genetics and experimental evolution study.Lancet Microbe. 2023 Apr;4(4):e247-e254. doi: 10.1016/S2666-5247(22)00356-1. Epub 2023 Feb 28. Lancet Microbe. 2023. PMID: 36868257 Free PMC article.
-
Neisseria gonorrhoeae ciprofloxacin susceptibility testing and gyrA targets.Lancet Microbe. 2023 Aug;4(8):e574. doi: 10.1016/S2666-5247(23)00149-0. Epub 2023 May 23. Lancet Microbe. 2023. PMID: 37236216 No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical